CTIS2023-508511-23-00进行中（未招募）1 期
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - A35-004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 664
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female, at least 18 years of age., Men must not plan to father a child or to provide sperm for donation for the duration of the trial and 3 months after the last dose of study drug., Diagnosis of ALS (clinically definite or clinically probable), made by a physician who is experienced with management of ALS, as defined by the World Federation of Neurology revised El Escorial criteria., Time since onset of first symptom of ALS should be <24 months., If the participant is to be treated with riluzole and/or edaravone during the course of the trial, then treatment with riluzole and/or edaravone was, at the time of the baseline visit, previously started and maintained at a stable regimen for at least 14 days for riluzole and/or for a full treatment cycle for edaravone., Capable of providing informed consent., Capable and willing to follow trial procedures including visits to the trial clinic, remote visits, and status reporting requirements., Women of childbearing potential (WOCBP; e.g., not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the trial and 3 months after the last dose of study drug., Women must not be pregnant or planning to become pregnant for the duration of the trial and 3 months after last dose of study drug., Men must agree to practice contraception for the duration of the trial and for at least 3 months after last dose of study drug
排除标准
- •Presence of tracheostomy or PAV., Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, according to Investigator judgment., Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if he/she were to participate in the trial, according to Investigator judgment, Previous treatment for ALS with cellular therapies or gene therapies, Currently enrolled on another trial involving use of an investigational therapy, Previous treatment with PB or taurursodiol within 30 days from Screening, Implantation of Diaphragm Pacing System, Currently or previously treated within the last 30 days or planned exposure to any prohibited medications., Slow Vital Capacity less than 55%., History of known allergy to Phenylbutyrate or bile salts., Abnormal liver function, Renal insufficiency as defined by estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 (obtained within 12 weeks from first dose)., Pregnant women (confirmed by a pregnancy test within 7 days of first dose) or women currently breastfeeding., Current severe biliary disease which may result in the Investigator medical judgment in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gangrene of the gallbladder, abscess of the gallbladder., History of Class III/IV heart failure (per New York Heart Association – NYHA)., Participant under severe salt restriction
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644